T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Immunity
View this publicationImmunity
View this publicationClinical nuclear medicine
View this publicationJournal of CME
View this publicationJournal of leukocyte biology
View this publicationFrontiers in genetics
View this publicationJournal of molecular cell biology
View this publicationFrontiers in tropical diseases
View this publicationEuropean journal of immunology
View this publicationCancer cell international
View this publicationJournal of cancer research and clinical oncology
View this publication